Shahverdyan Robert, Hentschel Dirk M
Vascular Access Center, Asklepios Clinic Barmbek, Hamburg, Germany.
Interventional Nephrology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Semin Dial. 2023 Mar;36(2):147-154. doi: 10.1111/sdi.13065. Epub 2022 Mar 7.
Hemodialysis is the predominant treatment modality for chronic kidney disease, with arteriovenous fistula (AVF) being considered to be the preferred type of long-term vascular access. Implantation of the external anastomotic VasQ™ support device during AVF creation has been suggested to improve the functional outcomes of AVFs. In the current study, we report the clinical outcomes when using the device with radial-cephalic AVF (RCAVF) creation in a large cohort over 3 years.
One hundred fifty RCAVFs were created between June 2018 and August 2021 with implantation of VasQ™. Time to maturation, cannulation characteristics, and assisted (AP) and secondary patency (SP) rates were analyzed.
In this predominantly male (68%), median 64 years old cohort, 150 VasQ™ devices were implanted. Physiological maturation was achieved in 142/150 (95%) and was unassisted in 133/150 (89%). Of those, 129 matured within 1 month and four additional AVFs within 165 days. Eight AVFs achieved maturation following percutaneous transluminal angioplasty, and one required surgical patch angioplasty. The median time from creation to first successful cannulation in dialysis patients was 41 days. AP at 6, 12, 18, 24, and 30 months was 89%, 81%, 78%, 73%, and 73%, and SP was 94%, 87%, 86%, 84%, and 84%, respectively.
Consistent use of the VasQ™ device in RCAVF creation demonstrates excellent AVF maturation and patency rates with very low frequency of assisted maturation and interventions for maintenance. The VasQ™ device appears a suitable aid in increasing the creation of functional RCAVFs.
血液透析是慢性肾脏病的主要治疗方式,动静脉内瘘(AVF)被认为是长期血管通路的首选类型。有人提出在建立AVF期间植入外部吻合VasQ™支撑装置可改善AVF的功能结局。在本研究中,我们报告了在3年多的时间里,在一大群患者中使用该装置建立桡动脉-头静脉内瘘(RCAVF)的临床结局。
2018年6月至2021年8月期间,共植入VasQ™装置建立了150例RCAVF。分析成熟时间、穿刺特点以及辅助通畅率(AP)和二次通畅率(SP)。
在这个以男性为主(68%)、中位年龄64岁的队列中,共植入了150个VasQ™装置。142/150(95%)实现了生理性成熟,其中133/150(89%)未借助辅助手段。其中,129个在1个月内成熟,另外4个AVF在165天内成熟。8个AVF在经皮腔内血管成形术后实现成熟,1个需要手术补片血管成形术。透析患者从建立内瘘到首次成功穿刺的中位时间为41天。6个月、12个月、18个月、24个月和30个月时的AP分别为89%、81%、78%、73%和73%,SP分别为94%、87%、86%、84%和84%。
在建立RCAVF时持续使用VasQ™装置显示出优异的AVF成熟率和通畅率,辅助成熟和维持干预的频率非常低。VasQ™装置似乎是增加功能性RCAVF建立的合适辅助工具。